Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. März 2015 07:00 ET | Quelle: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical to Present Xtampza ER(TM) Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting

CANTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company's completed Phase III clinical trial that evaluated the efficacy...
10. März 2015 07:00 ET | Quelle: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of Its Lead Abuse-Deterrent Product Candidate

CANTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent...
26. Februar 2015 07:00 ET | Quelle: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering DETERx(R), an Abuse-Deterrent, Extended-Release, Technology Platform

CANTON, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent...
17. Februar 2015 07:00 ET | Quelle: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Secures FDA Acceptance for Filing of NDA for XTAMPZA ER(TM) (Oxycodone Extended-Release Capsules), an Abuse-Deterrent Analgesic for Chronic Pain

CANTON, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent...